Interferon-lambda:New functions on intestinal symptoms in COVID-19  

作　　者：Yi-Yang Pan Liu-Can Wang Feng Yang Min Yu 

机构地区：[1]Department of General Surgery,Xinqiao Hospital,Army Medical University,Chongqing 400037,China [2]Department of General Surgery,Chongqing General Hospital,Chongqing 400013,China

出　　处：《World Journal of Gastroenterology》2023年第13期1942-1954,共13页世界胃肠病学杂志（英文版）

基　　金：Supported by National Natural Science Foundation of China(to M.Y.),No.81970468.

摘　　要：The tremendous public health and economic impact of coronavirus disease 2019(COVID-19), caused by severe acute respiratory syndrome coronavirus 2(SARSCoV-2), has become a huge challenge globally. There is increasing evidence that SARS-CoV-2 induces intestinal infections. Type Ⅲ interferon(IFN-λ) has an antiviral role in intestinal infection, with focused, long-lasting, and non-inflammatory characteristics. This review presents a summary of the structure of SARSCoV-2, including its invasion and immune escape mechanisms. Emphasis was placed on the gastrointestinal impact of SARS-CoV-2, including changes to the intestinal microbiome, activation of immune cells, and inflammatory responses.We also describe the comprehensive functions of IFN-λ in anti-enteric SARS-CoV-2 infection, and discuss the potential application of IFN-λ as a therapeutic agent for COVID-19 with intestinal symptoms.

关 键 词：COVID-19 SARS-CoV-2 Interferon-λ Gastrointestinal infection Mechanism Anti-viral response 

分 类 号：R511[医药卫生—内科学]